Escitalopram - CAS 128196-01-0
Catalog number: 128196-01-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C20H21FN2O
Molecular Weight:
324.39
COA:
Inquire
Targets:
SSRIs
Description:
Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD). Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram is found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
(S)-Citalopram; S-(+)-Citalopram; Seroplex
MSDS:
Inquire
1.A first screening and risk assessment of pharmaceuticals and additives in personal care products in waste water, sludge, recipient water and sediment from Faroe Islands, Iceland and Greenland.
Huber S1, Remberger M2, Kaj L2, Schlabach M3, Jörundsdóttir HÓ4, Vester J5, Arnórsson M6, Mortensen I7, Schwartson R8, Dam M9. Sci Total Environ. 2016 Apr 16;562:13-25. doi: 10.1016/j.scitotenv.2016.03.063. [Epub ahead of print]
A screening of a broad range of pharmaceuticals and additives in personal care products (PPCPs) in sub-arctic locations of the Faroe Islands (FO), Iceland (IS) and Greenland (GL) was conducted. In total 36 pharmaceuticals including some metabolites, and seven additives in personal care products were investigated in influent and effluent waters as well as sludge of waste water treatment plants (WWTPs) and in water and sediment of recipients. Concentrations and distribution patterns for PPCPs discharged via sewage lines (SLs) to the marine environment were assessed. Of the 36 pharmaceuticals or metabolites analysed 33 were found close to or above the limit of detection (LOD) in all or a part of the samples. All of the seven investigated additives in personal care products were detected above the LOD. Some of the analysed PPCPs occurred in every or almost every sample. Among these were diclofenac, ibuprofen, lidocaine, naproxen, metformin, citalopram, venlafaxine, amiloride, furosemide, metoprolol, sodium dodecyl sulphate (SDS) and cetrimonium salt (ATAC-C16).
2.Resting functional connectivity in social anxiety disorder and the effect of pharmacotherapy.
Doruyter A1, Lochner C2, Jordaan GP3, Stein DJ4, Dupont P5, Warwick JM6. Psychiatry Res. 2016 Apr 16;251:34-44. doi: 10.1016/j.pscychresns.2016.04.009. [Epub ahead of print]
Neuroimaging research has reported differences in resting-state functional connectivity (RFC) between social anxiety disorder (SAD) patients and healthy controls (HCs). Limited research has examined the effect of treatment on RFC in SAD. We performed a study to identify differences in RFC between SAD and HC groups, and to investigate the effect of pharmacotherapy on RFC in SAD. Seed-based RFC analysis was performed on technetium-99m hexamethylpropylene amine oxime (Tc-99m HMPAO) SPECT scans using a cross-subject approach in SPM-12. Seeds were chosen to represent regions in a recently published network model of SAD. A second-level regression analysis was performed to further characterize the underlying relationships identified in the group contrasts. Twenty-three SAD participants were included, of which 18 underwent follow-up measures after an 8-week course of citalopram or moclobemide. Fifteen healthy control (HC) scans were included. SAD participants at baseline demonstrated several significant connectivity disturbances consistent with the existing network model as well as one previously unreported finding (increased connectivity between cerebellum and posterior cingulate cortex).
3.Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
Lam RW1, Milev R2, Rotzinger S3,4, Andreazza AC4,5, Blier P6, Brenner C7, Daskalakis ZJ4,5, Dharsee M8, Downar J3,4, Evans KR8,9, Farzan F4,5, Foster JA3,10, Frey BN10, Geraci J3, Giacobbe P3,4, Feilotter HE8,9, Hall GB10, Harkness KL11, Hassel S12, Ismai BMC Psychiatry. 2016 Apr 16;16(1):105. doi: 10.1186/s12888-016-0785-x.
BACKGROUND: Major Depressive Disorder (MDD) is among the most prevalent and disabling medical conditions worldwide. Identification of clinical and biological markers ("biomarkers") of treatment response could personalize clinical decisions and lead to better outcomes. This paper describes the aims, design, and methods of a discovery study of biomarkers in antidepressant treatment response, conducted by the Canadian Biomarker Integration Network in Depression (CAN-BIND). The CAN-BIND research program investigates and identifies biomarkers that help to predict outcomes in patients with MDD treated with antidepressant medication. The primary objective of this initial study (known as CAN-BIND-1) is to identify individual and integrated neuroimaging, electrophysiological, molecular, and clinical predictors of response to sequential antidepressant monotherapy and adjunctive therapy in MDD.
4.Prescribing Pattern of Antidepressants in Children and Adolescents: Findings from the Research on Asia Psychotropic Prescription Pattern.
Chee KY1, Tripathi A2, Avasthi A3, Chong MY4, Xiang YT5, Sim K6, Kanba S7, He YL8, Lee MS9, Chiu HF10, Yang SY11, Kuga H7, Udomratn P12, Tanra AJ13, Maramis MM14, Grover S3, Mahendran R15, Kallivayalil RA16, Shen WW17, Shinfuku N18, Tan CH19, Sartorius N2 East Asian Arch Psychiatry. 2016 Mar;26(1):10-7.
OBJECTIVE: Pharmacotherapy of depression in children and adolescents is complex. In the absence of research into the efficacy and safety of antidepressants in this group of patients, their off-label prescription is common. This paper aimed to illustrate the prescription pattern of antidepressants in children and adolescents from major psychiatric centres in Asia.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related SSRIs Products


CAS 386750-22-7 Desvenlafaxine Succinate

Desvenlafaxine Succinate
(CAS: 386750-22-7)

Desvenlafaxine Succinate is a new serotonin (5-HT) transporter and norepinephrine (NE) transporter reuptake inhibitor with Ki of 40.2 nM and 558.4 nM respective...

CAS 101152-94-7 Milnacipran HCl

Milnacipran HCl
(CAS: 101152-94-7)

Milnacipran inhibits both norepinephrine transporter (NET) and norepinephrine transporter (SERT) with IC50 of 77 nM and 420 nM, respectively. Milnacipran at hig...

CAS 63302-99-8 Azaphen dihydrochloride monohydrate

Azaphen dihydrochloride monohydrate
(CAS: 63302-99-8)

Azaphen dihydrochloride monohydrate is a potent inhibitor of the reuptake of serotonin. It is a tricyclic antidepressant (TCA) approved in Russia for the treatm...

CAS 219861-08-2 Escitalopram Oxalate

Escitalopram Oxalate
(CAS: 219861-08-2)

Escitalopram Oxalate also known by the brand names Lexapro and Cipralex among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) ...

CAS 61718-82-9 Fluvoxamine maleate

Fluvoxamine maleate
(CAS: 61718-82-9)

Fluvoxamine maleate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and sigma-1 receptor agonist.

CAS 128196-01-0 Escitalopram

Escitalopram
(CAS: 128196-01-0)

Escitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Escitalopram...

CAS 136434-34-9 Duloxetine Hydrochloride

Duloxetine Hydrochloride
(CAS: 136434-34-9)

Duloxetine Hydrochloride is a serotonin-norepinephrine reuptake inhibitor with Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anx...

CAS 93413-62-8 Desvenlafaxine

Desvenlafaxine
(CAS: 93413-62-8)

Desvenlafaxine is a serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor with Ki of 40.2 nM and 558.4 nM, respectively.

CAS 93413-69-5 Venlafaxine

Venlafaxine
(CAS: 93413-69-5)

Venlafaxine is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class, but it has been referred to as a serotonin-norepinephrine-dopa...

CAS 54739-18-3 Fluvoxamine

Fluvoxamine
(CAS: 54739-18-3)

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. It is effective in inhibiting 5-ht uptake by blo...

CAS 99300-78-4 Venlafaxine hydrochloride

Venlafaxine hydrochloride
(CAS: 99300-78-4)

Venlafaxine hydrochloride is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class, but it has been referred to as a serotonin-norep...

CAS 175131-60-9 Levomilnacipran

Levomilnacipran
(CAS: 175131-60-9)

Levomilnacipran (brand name Fetzima) is an antidepressant approved for the treatment of major depressive disorder in the United States. It was developed by Fore...

CAS 79559-97-0 Sertraline HCl

Sertraline HCl
(CAS: 79559-97-0)

Sertraline HCl is a 5-HT antagonist with Ki of 13 nM.

CAS 56296-78-7 Fluoxetine hydrochloride

Fluoxetine hydrochloride
(CAS: 56296-78-7)

Fluoxetine is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression.

CAS 125494-59-9 Sibutramine hydrochloride monohydrate

Sibutramine hydrochloride monohydrate
(CAS: 125494-59-9)

A serotonin and noradrenaline reuptake inhibitor (SNR). Decreases calorie intake and increases energy expenditure.

CAS 110429-35-1 Paroxetine hydrochloride hemihydrate

Paroxetine hydrochloride hemihydrate
(CAS: 110429-35-1)

Paroxetine hydrochloride hemihydrate is a antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs).

CAS 24853-80-3 Azaphen

Azaphen
(CAS: 24853-80-3)

An antidepressant having effects on the autonomic nervous system; the drug is especially effective for mild and moderate depressions and a combination of Azaphe...

CAS 92623-85-3 Milnacipran

Milnacipran
(CAS: 92623-85-3)

Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) used in the clinical treatment of fibromyalgia. It is not approved for the clinical treatmen...

CAS 54910-89-3 Fluoxetine

Fluoxetine
(CAS: 54910-89-3)

class. It delays the reuptake of serotonin, resulting in serotonin persisting longer when it is released. It may also produce some of its effects via its weak 5...

CAS 19794-93-5 Trazodone

Trazodone
(CAS: 19794-93-5)

Trazodone, a phenylpiperazine compound, acts as a serotonin uptake inhibitor with antianxiety (anxiolytic) and sleep-inducing (hypnotic) effects.

Chemical Structure

CAS 128196-01-0 Escitalopram

Quick Inquiry

Verification code

Featured Items